Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum

NCT05964413 is registered in ClinicalTrials.gov with InflaRx GmbH as lead sponsor.

NCT NCT05964413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05964413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum
Lead sponsor
InflaRx GmbH
Phase
Phase 3
Overall status
Terminated
Start date
November 1, 2023
Completion date
July 11, 2025
Enrollment
54 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

pyoderma gangrenosum